Printer Friendly

Ask about pain in initial evaluations.

Pain is a frequent concomitant of psychiatric disorders--depression, anxiety, and somatoform disorders in particular--and psychiatric difficulties are common among the estimated 86 million Americans who suffer from chronic pain.

"In many cases, you can't treat one effectively without treating the other," said Dr. Rollin M. Gallagher, professor of psychiatry at the University of Pennsylvania, Philadelphia. "The relationship is a two-way street, and psychiatrists are uniquely qualified to deal with that complexity."

Questions about pain should be standard in the initial psychiatric evaluation. When patients under treatment for chronic pain are referred for management of emotional issues, "psychiatrists need to provide empathy and an understanding of their suffering, and help with healthy adaptation to the sick role," said Dr. John R. Sharp of Beth Israel Deaconess Medical Center and Harvard Medical School, Boston.

Clinicians should communicate with the patient's other health care providers and be familiar with comprehensive pain centers and other community resources.

The bidirectional relationship between pain and depression is well recognized. Nearly half of depressed individuals in one survey reported at least one painful physical condition of at least 6 months' duration (low back pain and headache were most common), a rate four times as high as that reported by a nondepressed population (Arch. Gen. Psychiatry 2003;60:39-47).

"Pain can cause depression. It can make depression worse, more difficult to treat, and less likely to go into remission," said Dr. David A. Fishbain, professor of psychiatry at the University of Miami and a staff member at the university's comprehensive pain center.

Noradrenergic and serotonergic systems are implicated in pain transmission, and antidepressants that affect both are the drugs of choice for chronic pain.

"Tricyclics probably have the highest efficacy for the treatment of pain, and serotonin norepinephrine reuptake inhibitors [SNRIs] the next greatest efficacy," Dr. Fishbain said. "Selective serotonin reuptake inhibitors have [the] least."

Because tricyclics at antidepressant dosages might be difficult to tolerate, the SNRIs venlafaxine (Effexor) and duloxetine (Cymbalta) have become first-line treatment for most psychiatrists.

Dr. Fishbain observed that duloxetine is the only antidepressant with Food and Drug Administration approval for pain, and he said that his experience with this drug has in general been "slightly better" than it has been with venlafaxine.

Robert L. Barkin, Pharm.D., prefers venlafaxine. He noted that the older agent poses little risk of drug-drug interactions, whereas duloxetine inhibits cytochrome P450 2D6, a liver enzyme system involved in the metabolism of other drugs, including opiates.

Hepatotoxicity concerns make alcohol use problematic for patients taking duloxetine, said Dr. Barkin, clinical pharmacologist at the Rush Pain Center in Chicago and the North Shore Pain Center in Skokie, Ill.

The dual-action antidepressants also have a role in treating chronic pain without depression. Here, too, venlafaxine is his drug of choice.

The rationale for this drug should be explained carefully to patients who are sensitive to implications about the psychogenic origins of their persistent pain. "I say that venlafaxine, although an antidepressant, isn't being used because they're depressed but because it affects the same spinal pain pathways as opiates," he said.

To minimize side effects, Dr. Barkin titrates very slowly: 37.5 mg/day for 15 days, 37.5 mg b.i.d. for another 2 weeks, then 75 mg b.i.d. Most patients respond at 150-225 mg/day.

A low-dose tricyclic is another option. Dr. Sharp said that he might consider this first, most often nortriptyline (10-25 mg/day) or an equivalent dosage of amitriptyline (25-50 mg). At these levels, which are well below those needed for antidepressant efficacy, the drugs are usually well tolerated. Serum levels can be monitored, he said.

For older patients and others in whom even low-dose tricyclics are contraindicated, poorly tolerated, or ineffective, he would probably opt for duloxetine, Dr. Sharp said.

Anticonvulsants have an important role for pain that is neuropathic in origin: diabetic peripheral neuropathy, postherpetic neuralgia, or trigeminal neuralgia.

According to Dr. Gallagher, this neuropathic category also includes low back pain with radiculopathy (sciatica), persistent pain that follows brachial plexus injury in a motor vehicle accident, repetitive motion injury like carpal tunnel syndrome, and the consequences of cancer chemotherapy, surgery, and radiation therapy.

Although various forms of neuropathic pain may involve different mechanisms and respond to different drugs, his first choice is frequently gabapentin (Neurontin), which is FDA approved for postherpetic neuralgia. "It's completely safe and doesn't react with anything else"--a particularly important consideration because many patients are taking anti-inflammatories and other drugs.

When prescribing gabapentin, "the big mistake is undertreatment," he said. In high-dose clinical trials, patients have received 3,600 mg/day, and he has prescribed doses as high as 5,000 mg. "Side effects tend to be minimal if you go up slowly," Dr. Gallagher said.

Pregabalin (Lyrica), recently approved for the pain of diabetic neuropathy as well as postherpetic neuralgia, is another option. Typical dosages are 150 mg b.i.d., he said.

The anticonvulsant that Dr. Barkin prefers is topiramate (Topamax), which he prescribes for neuropathic pain if venlafaxine fails. Topiramate affects neurotransmitters more broadly than other drugs, he pointed out, and causes weight loss.

For Dr. Fishbain, carbamazepine, an older anticonvulsant approved for one neuropathic pain indication--trigeminal neuralgia--has been effective for other indications as well.

"Some patients with complex regional pain syndrome have responded" to duloxetine, as have "some with fibromyalgia syndrome, which is now thought by many to be a neuropathic pain condition," he said.

Dr. Gallagher observed that polypharmacy is the rule when treating neuropathic pain. "You can't change the disease process itself. What you can do with each drug is incrementally turn the pain down," he said.

Anxiety frequently exacerbates chronic pain conditions: The association, notably in posttraumatic stress disorder and panic disorder, is in fact stronger than the one between pain and depression (Curr. Psychiatry Rep. 2005;7:213-9). A dual-action antidepressant such as venlafaxine, may be effective for these patients.

Low-dose benzodiazepines can have a role as well, Dr. Sharp said. When other central nervous system depressants, such as opioids, are prescribed, benzodiazepines must be used with particular caution and at the lowest practicable dose, he said.

By Carl Sherman, contributing writer
COPYRIGHT 2006 International Medical News Group
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2006 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:psychiatric evaluation
Author:Sherman, Carl
Publication:Clinical Psychiatry News
Geographic Code:1USA
Date:Jun 1, 2006
Words:1022
Previous Article:Oral appliances, surgery falling short for apnea.
Next Article:Trial data awaited on PFO closure for migraine relief.
Topics:


Related Articles
Kin urge Takuma be punished soon for school massacre.
PSN-2. Identification of the prodrome of schizophrenia.
Blade maniac ruined my life.
Essentials of Psychosomatic Medicine.
Advisory on varenicline warns of depression.
Doing mental healthcare right the first time: employers are paying more attention to the impact mental illness can have on the bottom line, but...
Post injury chronic low back pain and depression: comparative study between early and late post-injury sufferers shows significant difference.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters